secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0001628280-25-033612
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion appoints Craig Thompson to Board of Directors; board now has eight members
--------------------------------------------------------------------------------

- Craig Thompson appointed to Esperion Board as independent Class II director, effective July 1, 2025.
- Board expands from seven to eight members; Thompson will serve on Compliance, Nominating/Gov., and Commercial Committees.
- Thompson is CEO of Cerevance and has held leadership roles at Neurana, Anthera, Tetraphase, Trius, Pfizer, and Merck.
- He led commercial development of torcetrapib/atorvastatin at Pfizer and was involved in Trius' $700M+ acquisition by Cubist.
- Thompson holds a BComm from McMaster University and an MBA from the University of Notre Dame.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025033612/0001628280-25-033612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025033612/espr-20250701.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-033612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer